Polypodium leucotomos extract: A status report on clinical efficacy and safety

Richard R. Winkelmann, James Del Rosso, Darrell S. Rigel

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Various extracts of polypodium leucotomos (PLE) applied topically or taken orally have been shown to have several beneficial antioxidant, photoprotectant, antimutagenic, and immunoregulatory effects. Modern studies have evaluated the efficacy of PLE orally as a photoprotective agent and for use in several photo-aggravated dermatologic disorders such as polymorphous light eruption, other photodermatoses, and melasma. No articles have been published evaluating the safety of PLE. We performed a PUBMED search for any randomized clinical trials related to PLE, or anapsos, a synonym. The primary safety endpoint of the review was any mention of an adverse event, side effect, or toxicity. Overall, 19 human and 6 basic science studies were included spanning over 40 years of research. Oral PLE was administered at daily doses ranging from 120 mg to 1080 mg. No adverse effects were reported in laboratory studies. In humans, side effects (gastrointestinal complaints and pruritus) were mild to moderate and found only in very small numbers of patients overall (16/1016 [2%]). This review concludes PLE is well tolerated at all doses administered and associated with a negligible risk of side effects.

Original languageEnglish
Pages (from-to)254-259
Number of pages6
JournalJournal of Drugs in Dermatology
Volume14
Issue number3
StatePublished - 1 Mar 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Polypodium leucotomos extract: A status report on clinical efficacy and safety'. Together they form a unique fingerprint.

Cite this